Trending Topic

3 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Prithviraj Bose MD, EHA 2019 – Sotatercept in Subjects with MPN-associated Myelofibrosis and Anaemia

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jun 27th 2019

Professor Prithviraj Bose joins us at the EHA annual meeting in Amsterdam to discuss his presentation on sotatercept (ACE-011) in subjects with MPN-associated myelofibrosis and anaemia.

Questions
1. What are the limitations of ruxolitinib treatment for MPN-associated myelofibrosis? (0:05)
2. What is the mechanism of action of sotatercept? (0:55)
3. What is the rationale for combining sotatercept with ruxolitinib? (1:36)
4. Could you tell us a little about your recent phase II study of sotatercept and its findings? (2:27)
5. Which other emerging therapies for MPN-associated myelofibrosis seem promising? (3:48)

Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.

touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup